hydrazine has been researched along with Intracranial Hemorrhages in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolster, L; Goodyear, MD; Patterson, JM; Podstawka, J; Rydz, N; Sun, HL; Wall, E | 1 |
| Agard, C; Boisseau, P; Denis, CV; Espitia, O; Fouassier, M; Ternisien, C | 1 |
2 other study(ies) available for hydrazine and Intracranial Hemorrhages
| Article | Year |
|---|---|
Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
Topics: Adult; Canada; Chronic Disease; Hemorrhage; Humans; Hydrazines; Intracranial Hemorrhages; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Thrombocytopenia; Thrombopoietin | 2022 |
Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage.
Topics: Amino Acid Substitution; Benzoates; Female; Humans; Hydrazines; Intracranial Hemorrhages; Middle Aged; Mutation, Missense; Pyrazoles; Receptors, Thrombopoietin; Thrombocytopenia; von Willebrand Disease, Type 2; von Willebrand Factor | 2017 |